Gerasimos Siasos*, Panagiota K. Stampouloglou, Evanthia Bletsa, Stavroula A. Paschou, Evangelos Oikonomou, Georgios Giannopoulos, Spyridon Deftereos, Michael W. Cleman and Dimitrios Tousoulis Pages 3905 - 3907 ( 3 )
Type 2 diabetes mellitus, SGLT-2i, heart failure, cardiovascular, CVD, glucose.
Unit of Heart and Diabetes, First Department of Cardiology, Hippokration Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Unit of Heart and Diabetes, First Department of Cardiology, Hippokration Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Unit of Heart and Diabetes, First Department of Cardiology, Hippokration Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Unit of Heart and Diabetes, First Department of Cardiology, Hippokration Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Unit of Heart and Diabetes, First Department of Cardiology, Hippokration Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, Unit of Heart and Diabetes, First Department of Cardiology, Hippokration Hospital, Medical School, National and Kapodistrian University of Athens, Athens